GHK-Cu is a naturally occurring copper-binding tripeptide that has been studied in laboratory and cosmetic research. It is often discussed for skin appearance, hair and tissue repair, but the evidence and regulatory considerations depend heavily on how the product is used.
Copper peptides are used in some topical cosmetic products. Cosmetic use should not be confused with injection or systemic administration. Evidence from topical formulations cannot automatically be applied to injectable products.
The FDA lists GHK-Cu for injectable routes among bulk drug substances that may present significant safety risks in compounding. The agency cites potential immunogenicity, peptide-related impurities and limited human data to characterize injectable safety.
FDA: Bulk Drug Substances That May Present Significant Safety Risks
GHK-Cu has biological effects that have generated interest in skin and wound-healing research, and topical copper peptides appear in cosmetic formulations. However, claims about reversing aging, restoring damaged tissue or producing medical-grade regenerative effects should be separated from what has actually been established in controlled human studies.
Copper peptides are marketed in some hair products, but they should not replace evaluation for common causes of hair loss such as androgenetic alopecia, thyroid disease, iron deficiency, medication effects or other scalp disorders.
Unapproved injectable peptides may carry risks related to sterility, dosing, product identity, contamination, impurities and immune reactions. Products sold online or labeled “research use only” are not established human treatments.
GHK-Cu is not an FDA-approved injectable drug for anti-aging, hair growth, wound healing or general regenerative treatment. FDA specifically lists injectable GHK-Cu among compounded bulk substances for which it has identified potential safety concerns and limited human data.
No. Topical cosmetic exposure and systemic injection are different routes with different risk and evidence considerations. Findings from cosmetic or laboratory research should not be used to assume injectable safety or effectiveness.
Copper peptides are included in some hair and scalp products, but evidence does not support using them as a substitute for diagnosing common causes of hair loss. Treatment should be directed at the underlying diagnosis.
Consider the route, intended use, product source, evidence and regulatory status. Injectable products require particular caution because sterility, identity, potency, impurities and immune reactions can affect safety.
We review the exact compound, route of administration, FDA status and quality of human evidence before discussing a peptide. When an FDA-approved or better-supported alternative exists, that evidence is part of the decision.
For a broader overview, visit our Peptide Therapy and Medical Evaluation page or our peptide safety and FDA-status guide.
David Nazarian, M.D., is Board-Certified in Internal Medicine and provides physician-led hormone evaluation and individualized care for women and men. His approach emphasizes comprehensive assessment, patient education, individualized treatment, safety, and ongoing follow-up. Dr. Nazarian specializes in bio-identical hormone replacement therapy in men & women. He has extensive training and knowledge in treating andropause and testosterone replacement therapy in men and menopause and estrogen replacement therapy in women. Supported by his experienced medical team, Dr. Nazarian treats men and women with hormone deficiencies and imbalances and enjoys the one-on-one relationship between patient and doctor.
Copyright ©2026 Hormone Replacement Therapy LA. All rights reserved.